{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:04:11Z","timestamp":1790885051639,"version":"4.1.0"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,8]]},"DOI":"10.7759\/cureus.30080","type":"journal-article","created":{"date-parts":[[2022,10,9]],"date-time":"2022-10-09T01:23:27Z","timestamp":1665278607000},"source":"Crossref","is-referenced-by-count":3,"title":["High-Intensity Statin With Severe Consequences: A Case of Non-autoimmune Rosuvastatin-Induced Myonecrosis"],"prefix":"10.7759","author":[{"given":"Mariam","family":"Hassan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Helmsdoerfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahithi","family":"Nadella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aymara","family":"Chang Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/s0735-1097(02)02030-2","article-title":"ACC\/AHA\/NHLBI clinical advisory on the use and safety of statins","volume":"40","author":"Pasternak RC","year":"2002","unstructured":"Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC\/AHA\/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol. 2002, 40:567-72. 10.1016\/s0735-1097(02)02030-2","journal-title":"J Am Coll Cardiol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000678","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines","volume":"140","author":"Arnett DK","year":"2019","unstructured":"Arnett DK, Blumenthal RS, Albert MA, et al.. 2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines. Circulation. 2019, 140:e596-646. 10.1161\/CIR.0000000000000678","journal-title":"Circulation"},{"key":"ref3","unstructured":"Statin Use for the Primary Prevention of Cardiovascular Disease in Adults. Preventive Medication. (2022). Accessed: May 10, 2022: https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/recommendation\/statin-use-in-adults-preventive-medication."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2014.03.004","article-title":"An assessment by the Statin Muscle Safety Task Force: 2014 update","volume":"8","author":"Rosenson RS","year":"2014","unstructured":"Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA, The National Lipid Association's Muscle Safety Expert Panel. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol. 2014, 8:S58-71. 10.1016\/j.jacl.2014.03.004","journal-title":"J Clin Lipidol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.22.2671","article-title":"Outcomes in 45 patients with statin-associated myopathy","volume":"165","author":"Hansen KE","year":"2005","unstructured":"Hansen KE, Hildebrand JP, Ferguson EE, Stein JH. Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med. 2005, 165:2671-6. 10.1001\/archinte.165.22.2671","journal-title":"Arch Intern Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/MOL.0b013e32825a6773","article-title":"The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis","volume":"18","author":"Harper CR","year":"2007","unstructured":"Harper CR, Jacobson TA. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis. Curr Opin Lipidol. 2007, 18:401-8. 10.1097\/MOL.0b013e32825a6773","journal-title":"Curr Opin Lipidol"},{"key":"ref7","article-title":"Drug induced muscle disorders","volume":"28","author":"Smithson J","year":"2009","unstructured":"Smithson J. Drug induced muscle disorders. Australian Pharmacist. 2009, 28:1056-62.","journal-title":"Australian Pharmacist"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/00131402-200203000-00001","article-title":"Amiodarone-induced neuromyopathy: three cases and a review of the literature","volume":"3","author":"Pulipaka U","year":"2002","unstructured":"Pulipaka U, Lacomis D, Omalu B. Amiodarone-induced neuromyopathy: three cases and a review of the literature. J Clin Neuromuscul Dis. 2002, 3:97-105. 10.1097\/00131402-200203000-00001","journal-title":"J Clin Neuromuscul Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/114152-high-intensity-statin-with-severe-consequences-a-case-of-non-autoimmune-rosuvastatin-induced-myonecrosis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:50:43Z","timestamp":1707508243000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/114152-high-intensity-statin-with-severe-consequences-a-case-of-non-autoimmune-rosuvastatin-induced-myonecrosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,8]]},"references-count":8,"URL":"https:\/\/doi.org\/10.7759\/cureus.30080","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,8]]}}}